Side-by-side · Research reference
PancragenvsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED23/39 cited
BPhase 3HUMAN-REVIEWED25/54 cited
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
Pancragen
Survodutide
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
Yes — preserves physiological glucose-insulin response
—
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
—
Antibody development
—
—
02Dosage Protocols
Parameter
Pancragen
Survodutide
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
—
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
—
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Phase 2 RCT (obesity) · Phase 3 ongoing
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
—
03Metabolic / Fat Loss Evidence
Parameter
Pancragen
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
Pancragen
Survodutide
Reported adverse events
None documented in primate studies
—
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Injection site reactions
—
Expected with subcutaneous administration
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
Pancragen
—Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
Pancragen
Survodutide
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
—
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.